Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Executive Summary
Limited population approval pathway in 21st Century Cures law may not help Cempra overcome US agency's request for new 9,000-patient safety study of the macrolide antibiotic.
You may also be interested in...
QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications
Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.